Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Intrahepatic Cholangiocarcinoma (Icc): early-phase trial registry
2 of 2 indexed Intrahepatic Cholangiocarcinoma (Icc) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Intrahepatic Cholangiocarcinoma (Icc): 2 US clinical trials tracked, 2 recruiting.
Intrahepatic Cholangiocarcinoma (Icc) is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Cogent Biosciences, running 1 of these trials.
Enrollment posture brief
Registry condition intrahepatic-cholangiocarcinoma-icc
OPEN 2 | RECR 100% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Intrahepatic Cholangiocarcinoma (Icc) lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Intrahepatic Cholangiocarcinoma (Icc) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Intrahepatic Cholangiocarcinoma (Icc) is recruiting above its size-band peers.
2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
Cogent Biosciences
NCT06777316
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
National Cancer Institute (NCI)
NCT05286814
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Intrahepatic Cholangiocarcinoma (Icc) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Intrahepatic Cholangiocarcinoma (Icc) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Intrahepatic Cholangiocarcinoma (Icc) page
2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Intrahepatic Cholangiocarcinoma (Icc) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Cogent Biosciences sponsors the most Intrahepatic Cholangiocarcinoma (Icc) trials on record, review their full trial history before evaluating a specific study. See Cogent Biosciences's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Intrahepatic Cholangiocarcinoma (Icc) condition card totals 2 registered trials; most-linked intervention Floxuridine; top US site state Utah. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.